FUT2 secretor status — the testable genetic variable

The FUT2 gene controls whether a person is a 'secretor' — someone who expresses ABO blood-group antigens on the lining of their gut and in bodily fluids like saliva and breast milk. About one in five Europeans carries two broken copies of this gene and is a 'non-secretor,' a status that can be identified with a single, cheap SNP test (rs601338) available on most consumer genotyping platforms. This review synthesizes the mechanistic and clinical consequences of that genotype: non-secretors have a measurably less diverse gut microbiome, altered susceptibility to pathogens such as norovirus and H. pylori that use FUT2-dependent sugar structures as docking sites, and elevated rates of vitamin B12 malabsorption. Non-secretors are also at significantly higher risk for Crohn's disease, making secretor status a genuinely actionable variable in an IBD workup. The key clinical insight is that this is not a pharmacogenomic curiosity — it is a host-genetics variable that reshapes the mucosal environment in which the microbiome operates. Knowing a patient's secretor status can shift differential weighting for mucosal disease and may inform probiotic selection, because many probiotic strains colonize differently depending on whether FUT2-dependent glycan anchors are present. The article frames FUT2 testing as a low-cost, high-information-density step for clinicians working at the intersection of mucosal immunology, IBD, and microbiome medicine.

• Approximately 20% of Europeans are non-secretors, defined as homozygous for loss-of-function FUT2 alleles (most commonly W143X / G428A); the causal SNP is rs601338, detectable on standard consumer genotyping arrays.
• Non-secretor status is associated with increased susceptibility to Crohn's disease (McGovern et al 2010, https://pubmed.ncbi.nlm.nih.gov/20570966/" target="_blank" rel="noopener noreferrer" title="Open PMID:20570966 on PubMed/PMC">PMID:20570966), a less diverse gut microbiome with altered dominant species (Rausch et al PNAS 2011), and higher rates of vitamin B12 malabsorption.
• Pathogens that use FUT2-dependent α-1,2-fucosylated glycan structures as host-cell receptors — including norovirus, certain H. pylori strains, and some pathogenic E. coli — show differential infection and colonization rates by secretor status, meaning non-secretors are protected from some infections but susceptible to others.
• Probiotic colonization efficiency differs by secretor genotype, because several beneficial strains depend on FUT2-expressed mucosal glycans for attachment — a clinically relevant interaction that is invisible without genotyping.
• The FUT2 locus represents a rare convergence point where a single testable SNP influences microbiome composition, mucosal immunity, pathogen susceptibility, and nutrient absorption simultaneously.

This is a mechanism review article rather than a primary clinical trial; it synthesizes published GWAS data, microbiome profiling studies, and in vitro/in vivo mechanistic work centered on the FUT2 locus. Key primary sources include the McGovern et al 2010 IBD GWAS (https://pubmed.ncbi.nlm.nih.gov/20570966/" target="_blank" rel="noopener noreferrer" title="Open PMID:20570966 on PubMed/PMC">PMID:20570966), Rausch et al PNAS 2011 (microbiome composition by secretor status), and Kashyap et al PNAS 2013 (host-glycan–microbiome interaction). No original patient cohort or intervention arm is reported; the study design is narrative-mechanistic synthesis with supporting citation of human genetic and microbiome datasets.

As a mechanism review, this article cannot establish effect sizes, odds ratios, or causality beyond what its cited primary studies report — readers requiring quantitative risk estimates should consult the source GWASs directly. The 20% non-secretor prevalence figure is specific to European-ancestry populations; allele frequencies and functional variants differ substantially across ancestries (e.g., different loss-of-function SNPs predominate in African and East Asian populations), limiting direct generalizability. The review does not address gene-environment interactions — for example, whether diet, antibiotic history, or existing dysbiosis modifies the phenotypic impact of non-secretor status. The next clarifying experiments would be prospective cohort studies genotyping FUT2 at enrollment and tracking microbiome composition, pathogen exposure outcomes, and IBD incidence longitudinally across diverse ancestries.

This review of FUT2 secretor genetics sits at the intersection of host genetics and mucosal microbiome biology, and extends the conceptual framework developed in [§150], which addresses how gut microbiota composition drives immune-inflammatory disease — here, FUT2 status is positioned as an upstream host-genetic determinant of the very microbiota configurations that [§150] treats as inputs. It parallels [§147], which examines another single host variable (vitamin D status) with outsized influence on IBD risk and mucosal immune tone, reinforcing a pattern in this corpus where individual, testable host factors substantially modify gut inflammatory susceptibility. The article also parallels [§155], which investigates how Saccharomyces boulardii modulates intestinal barrier function — a mechanistic question that FUT2 genotype directly complicates, since barrier glycan architecture depends on secretor status. Finally, it provides genetic context that enriches [§153], which examines probiotic intervention in infants exposed to early antibiotics: because probiotic colonization efficiency is FUT2-dependent, secretor status is a confounding variable that none of the intervention studies in this corpus appear to have stratified on, representing a methodological gap across the topic.

• The Role of Vitamin D in Inflammatory Bowel Disease: Clinical Relevance and Therapeutic Potential
  Closest structural parallel: both articles examine a single, clinically testable host variable (FUT2 genotype vs. vitamin D status) that modulates IBD risk and mucosal immune function — comparing them reveals how genetic vs. nutritional determinants of gut inflammation interact.
• Editorial: The role of gut microbiota in immune-related inflammatory diseases
  Directly complementary mechanism: this editorial on gut microbiota in immune-inflammatory disease treats microbiome composition as the independent variable, while FUT2 secretor status is one of the key host-genetic factors shaping that composition — reading both clarifies the direction of causality.
• Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
  FUT2 secretor status determines mucosal glycan display that many probiotic strains use for attachment; comparing with this Saccharomyces boulardii barrier-function study highlights a likely confound in probiotic efficacy trials that do not stratify by secretor genotype.
• Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life
  Probiotic intervention in antibiotic-exposed infants is precisely the clinical scenario where FUT2 genotype would be expected to modify colonization outcomes — placing this review alongside [id=153] exposes a stratification gap in the intervention literature.
• Mechanism of FODMAP Restriction on FGID Patients
  FODMAP restriction affects fermentable substrate availability and microbiome composition; since non-secretors already have structurally different mucosal glycan environments, comparing these articles raises the question of whether secretor status modifies FODMAP treatment response in IBS/IBD overlap patients.